|
17 Jan 2019 |
First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients
|
|
15 Jan 2019 |
FDA Approves Expanded Use of Adacel® (Tdap) Vaccine for Repeat Vaccination
|
|
08 Jan 2019 |
PrimeVax Immuno-Oncology Receives IND Permission From FDA
|
|
07 Jan 2019 |
Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate
|
|
03 Jan 2019 |
Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a Clinical Trial for Neoantigen Vaccine Candidate GEN-009
|
|
30 Dec 2018 |
Emergent BioSolutions Announces Submission to FDA of Application Covering Emergency Use Authorization for NuThrax
|
|
27 Dec 2018 |
FDA Approves VAXELIS(TM), Sanofi and MSD's Pediatric Hexavalent Combination Vaccine
|
|
22 Dec 2018 |
Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17
|
|
22 Dec 2018 |
Bavarian Nordic Announces FDA Acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox Vaccine
|
|
21 Dec 2018 |
Independent Data Monitoring Committee Recommends Discontinuation of the Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Following Planned Interim Analysis
|
|
20 Dec 2018 |
Aimmune Therapeutics Announces IND Filing for AR201 for Egg Allergy and Exclusive Supply Agreement with Michael Foods
|
|
20 Dec 2018 |
HOOKIPA Doses First Patient in a Phase 2 Clinical Trial of Prophylactic Vaccine Candidate HB-101 against Cytomegalovirus
|
|
20 Dec 2018 |
Aimmune Therapeutics Initiates Phase 3 POSEIDON Trial for Treatment of Peanut Allergy in 1–3-Year-Old Children
|
|
20 Dec 2018 |
ILiAD Biotechnologies Secures Up to $20 million of Financing and Phase 2a BPZE1 Pertussis Vaccine Trial Initiates at Vanderbilt University Medical Center
|
|
19 Dec 2018 |
Dengvaxia® vaccine approved for prevention of dengue in Europe
|
|
17 Dec 2018 |
Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate
|
|
15 Dec 2018 |
VAXIMM Initiates Phase I/II Trial with VXM01 Oral T-cell Immunotherapy in Combination with PD-L1 Inhibitor Avelumab in Glioblastoma
|
|
15 Dec 2018 |
Anergis Reports Positive Preclinical Proof-of Concept Data of the Second-Generation COP Allergy Vaccine
|
|
14 Dec 2018 |
Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
|
|
06 Dec 2018 |
Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma
|
|
04 Dec 2018 |
Phase 2 cancer study will evaluate T cell-activating immunotherapy MEDI0457 with MedImmune’s durvalumab targeting several HPV-related cancers
|
|
03 Dec 2018 |
Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of G100 and Pembrolizumab
|
|
28 Nov 2018 |
Generex Biotechnology Signs Clinical Trial Agreement With the NSABP Foundation, Inc. for Phase II Clinical Trial of AE37 in Combination With Pembrolizumab (Keytruda®) for Treatment of Triple-Negative Breast Cancer
|
|
26 Nov 2018 |
SELLAS Life Sciences Announces Completion of Enrollment in Phase 2 Randomized Controlled Clinical Study of Nelipepimut-S Plus Trastuzumab in High-risk, High-expression HER2 Breast Cancer Patients
|
|
20 Nov 2018 |
Stallergenes Greer Announces That the Phase III Trial for Its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved Its Primary Endpoint
|
